Canada markets closed

ANI Pharmaceuticals, Inc. (ANIP)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
61.71-0.02 (-0.03%)
At close: 04:00PM EDT
61.71 0.00 (0.00%)
After hours: 04:20PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close61.73
Open61.61
Bid61.52 x 100
Ask61.79 x 200
Day's Range61.14 - 62.46
52 Week Range44.27 - 70.81
Volume81,695
Avg. Volume162,166
Market Cap1.294B
Beta (5Y Monthly)0.81
PE Ratio (TTM)38.33
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    ANI Pharmaceuticals Announces the Launch of Kionex® Suspension

    BAUDETTE, Minn., May 20, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Kionex® (Sodium Polystyrene Sulfonate Suspension USP) for Oral or Rectal use. Kionex® Suspension is the only commercially available therapeutically equivalent to the reference listed drug (RLD) SPS® Suspension for Oral or Rectal use. "The launch of Kionex® Suspension for Oral or Rectal use exemplifies our capability to bring complex generics with limited m

  • GlobeNewswire

    ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance

    Generated record quarterly net revenues of $137.4 million, representing year-over-year growth of 28.7%, net income to common shareholders of $17.8 million, and GAAP diluted earnings per share of $0.82Delivered record adjusted non-GAAP EBITDA of $37.6 million, and adjusted non-GAAP diluted earnings per share of $1.21Rare Disease business delivered Q1 net revenues of $36.9 million, representing year-over-year growth of 126.2%Reiterated 2024 guidance of net revenues of $520 million to $542 million,

  • GlobeNewswire

    ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences

    BAUDETTE, Minn., May 01, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will participate at two upcoming healthcare conferences in New York City as follows: Capital One 1st Annual Biotech/Biopharma Disruptors Event Date:Tuesday, May 14, 2024 Time:12:15pm ET To schedule a 1x1 meeting with management, please contact kristen.patrick@capitalone.com H.C. Wa